Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics (PRQR) Non-Current Deffered Revenue (2017 - 2025)

ProQR Therapeutics' Non-Current Deffered Revenue history spans 6 years, with the latest figure at $24.9 million for Q4 2025.

  • On a quarterly basis, Non-Current Deffered Revenue fell 20.81% to $24.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $24.9 million, a 20.81% decrease, with the full-year FY2025 number at $24.9 million, down 20.81% from a year prior.
  • Non-Current Deffered Revenue hit $24.9 million in Q4 2025 for ProQR Therapeutics, down from $31.4 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for PRQR hit a ceiling of $69.6 million in Q1 2023 and a floor of $687.55 in Q1 2021.
  • Historically, Non-Current Deffered Revenue has averaged $31.4 million across 5 years, with a median of $24.2 million in 2021.
  • The widest YoY moves for Non-Current Deffered Revenue: up 2211913.24% in 2022, down 51.83% in 2022.
  • Tracing PRQR's Non-Current Deffered Revenue over 5 years: stood at $16.8 million in 2021, then soared by 298.15% to $66.9 million in 2022, then fell by 28.96% to $47.5 million in 2023, then crashed by 33.83% to $31.4 million in 2024, then dropped by 20.81% to $24.9 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for PRQR at $24.9 million in Q4 2025, $31.4 million in Q4 2024, and $47.5 million in Q4 2023.